Podcast Episode 76 – Philip Low Cancer Research Update
This Is Purdue, the official podcast for Purdue University, highlights stories about Boilermakers from across all disciplines, who through research, innovation and determination, have persistently pursued their next giant leap.
Hosted by Purdue University alum, Brian Lamb School of Communication graduate, and Indiana native Kate Young, “This Is Purdue” aims to examine all of the incredible accomplishments of Boilermakers and their contributions to the world.
Below, you’ll find helpful information, stories, and social media content regarding this episode of This Is Purdue.
In this episode of “This Is Purdue,” we’re sharing a new update from our conversation with Boilermaker innovator Philip Low.
Professor Low, Purdue University’s Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, helped develop Cytalux, a fluorescent marker that allows cancer surgeons to quickly identify malignant cells and remove them during surgery. The Food and Drug Administration approved the drug in November 2021 for ovarian cancer, and in December 2022, the FDA approved Cytalux to help doctors during lung cancer surgery as well.
Based on foundational intellectual property developed at Purdue University and released by On Target Laboratories, this newly authorized use of Cytalux has the potential to improve the outcomes of thousands of patients, helping surgeons to visualize otherwise undetected cancer tissue in 24% of lung cancer patients in a clinical trial.
In this episode, professor Low discusses how the drug works, why the team started using it for ovarian cancer patients first, and what attracted him to innovation at Purdue University. Listen as we share more details about one of the most popular “This Is Purdue” episodes to date.
· Links to the podcast
· Social graphics
· Suggested social post copy
LINKS and UTM PARAMETERS
When you link to Purdue websites from social platforms or emails, we recommend that you add UTM parameters to the URL in order to provide reporting on the activity. The Marketing and Communications campaign URL builder allows you to easily configure these links and even request shortened Purdue-branded links.
UTM campaign: this_is_purdue_philip_low_cytalux_update
UTM medium: Social (or email)
UTM source: Facebook, Twitter, LinkedIn, Instagram (or email newsletter name)
Link to the podcast: https://stories.purdue.edu/podcast/philip-low-cytalux-update
General podcast page: https://stories.purdue.edu/podcast/
The following assets are available for download and use. Social assets include files for Twitter, Facebook, LinkedIn, Instagram and Instagram Stories.
SOCIAL MEDIA GUIDANCE POSTING TIPS
Digital engagement is a powerful platform to share Purdue stories and posts with past, present and future Boilermakers. Here are some tips to help your posts shine:
· Keep posts short and direct
· Link all posts back to our landing page
· Include photos, videos or GIFs
· Use short URLs
SUGGESTED SOCIAL MEDIA POSTS
LinkedIn + Facebook
- We’re featuring an exciting update on the latest episode of #ThisIsPurdue. Based on pioneering work by @PurdueScience professor Philip Low, Cytalux, the first fluorescent marker for ovarian cancer, is now authorized for use in lung cancer surgeries. Listen as professor Low discusses Cytalux’s potentially life-changing impact and learn more about the research taking place at #Purdue: <link>
- #ThisIsPurdue is sharing an important achievement from @PurdueCancerResearch: A new use of an imaging agent that will help surgeons find even more cancerous cells has been approved by the @FDA. The imaging agent, Cytalux, is based on pioneering work by @PurdueScience professor Philip Low, who continues to help develop innovative fluorescent dyes. “I think what attracted me to innovation was the opportunity to do something that matters,” Low says. Hear more about Cytalux on the official university podcast: <link>
Twitter + Instagram
- We’re featuring an exciting update on the latest episode of #ThisIsPurdue. Based on pioneering work by @PurdueScience professor Philip Low, Cytalux, the first fluorescent marker for ovarian cancer, is now authorized for use in lung cancer surgeries. Listen today: <link>
- A new use of an imaging agent that will help surgeons find even more cancerous cells has been approved by the @US_FDA. The imaging agent, Cytalux, is based on pioneering work by @PurdueScience prof. Philip Low. Listen to his interview on #ThisIsPurdue: <link>
- In our latest #ThisIsPurdue episode, you’ll learn more about cancer research at #Purdue and the imaging agent Cytalux, newly approved by the @US_FDA for use in lung cancer surgeries. Listen to this update from our 2022 episode with @PurdueScience prof. Philip Low: <link>
- The @US_FDA has approved the use of Cytalux, an imaging agent that illuminates cancer tumors, to help doctors during lung cancer surgery. Hear more from @PurdueScience prof. Philip Low on #ThisIsPurdue. @PUCancerCenter <link>
- Newly approved by the @US_FDA for use in lung cancer surgeries, Cytalux was first authorized for identifying ovarian cancer. Listen to @PurdueScience prof. Philip Low on #ThisIsPurdue for details on his pioneering work. <link>
Please tag Purdue University and use the hashtag #ThisIsPurdue
Other tagging options include:
CAMPAIGN SPECIFIC HASHTAGS
#MySmallStep = Student stories
#MyGiantLeap = Faculty/Alumni stories